Technology | June 28, 2006

Minimally Invasive Laser Solution for Atrial Fibrillation

A 1064 nm wavelength laser technology, the Atrilaze Surgical Ablation system complements its existing 810 nm technology.
The system is indicated for delivery of laser light to soft tissue, including cardiac tissue, during surgical procedures. Indications include the incision, excision, dissection, vaporization, ablation or coagulation of soft tissue.
Because it can be delivered through a 600 micron optical fiber, the Atrilaze system is designed for very small incisions, potentially enabling a stand-alone (closed-chest, beating heart) procedure.


Related Content

News

Oct. 10, 2025 — Johnson & Johnson MedTech, in collaboration with the Heart Rhythm Clinical and Research Solutions, LLC ...

Home October 13, 2025
Home
News

Sept. 2, 2025 — Johnson & Johnson MedTech has announced acute safety and effectiveness results from the Varipure ...

Home September 05, 2025
Home
News

Sept. 3, 2025 — Kardium Inc. recently announced it has received pre-market approval (PMA) for the Globe Pulsed Field ...

Home September 03, 2025
Home
News

July 14, 2025  –  Johnson & Johnson MedTech has announced U.S. Food and Drug Administration (FDA) approval of an update ...

Home July 14, 2025
Home
News

July 7, 2025 — Catheter ablation is a minimally invasive treatment for abnormal heart rhythms. It is often successful in ...

Home July 09, 2025
Home
News

June 4, 2025 — A new study published in The Annals of Thoracic Surgery, a journal from The Society of Thoracic Surgeons ...

Home June 04, 2025
Home
News

April 24, 2025 – The Heart Rhythm Society (HRS) and the American College of Cardiology (ACC) have released a scientific ...

Home April 24, 2025
Home
News

April 9, 2025 — Merit Medical Systems has announced the U.S. commercial release of its Ventrax Delivery System. Ventrax ...

Home April 16, 2025
Home
News

March 27, 2025 — Abbott recently announced it has received CE Mark in Europe for the Volt PFA System to treat patients ...

Home March 27, 2025
Home
News

Oct. 24, 2024 — Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera ...

Home October 30, 2024
Home
Subscribe Now